SARS-CoV-2 B.1.1.7 Variant (UK) Spike RBD (N501Y) Mutant Protein
Recombinant protein of receptor binding domain (RBD, Arg319-Phe541) of severe acute respiratory syndrome coronavirus 2 UK variant (SARS-CoV-2 variant B.1.1.7, RBD N501Y, NC_045512.2), with a polyhistidine tag
>90% by SDS-PAGE gel and Coomassie Blue staining
Antigens, Western, ELISA and other in vitro binding or in vivo functional assays, and protein-protein interaction studies; For research & development use only!
Purified protein formulated in a sterile solution of PBS buffer, pH7.2, without any preservatives
Endotoxin level is < 0.1 ng/µg of protein (<1EU /µg)
The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. The SARS-CoV-2 spike (S) protein is composed of two subunits; the S1 subunit contains a receptor-binding domain that engages with the host cell receptor angiotensin-converting enzyme 2 and the S2 subunit mediates fusion between the viral and host cell membranes. The S RBD protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity, during infection with SARS-CoV-2 (2019-nCoV) as in recent COVID-19 outbreak.
Fig 1 : SDS-Page Image
Customers who come to this page are also interested in the following products:
There's no citations at this moment.
There's no FAQs at this moment.
There's no reviews at this moment.